TrialBreast cancer research and treatment2025

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.

Sneha Phadke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.